查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1631918

造血幹細胞移植市場 - 全球產業規模、佔有率、趨勢、機會和預測，按類型、適應症、應用、最終用戶、地區和競爭細分，2020-2030F

Hematopoietic Stem Cell Transplantation Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Indication, By Application, By End User, By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年全球造血幹細胞移植市值為28.9億美元，預計2030年將達到43.3億美元，預測期內複合年成長率為6.93%。造血幹細胞移植（HSCT），也稱為骨髓移植，是一種用於治療各種血液和免疫疾病的醫療程序。 HSCT 的主要目標是以健康的骨髓和免疫細胞取代或修復受損或故障的骨髓和免疫細胞。造血幹細胞有潛力發育成不同類型的血細胞，對此過程至關重要。此過程涉及從患者的骨髓、周邊血或臍帶血中採集造血幹細胞。或者，可以使用來自相容供體的幹細胞。在移植之前，患者要接受預處理，通常包括化療和/或放射治療。這有助於消除現有的患病細胞並為新的幹細胞創造有利的環境。調理階段後，收穫或捐贈的幹細胞被注入患者的血液中。這些細胞遷移到骨髓，在那裡開始產生健康的血細胞，包括紅血球、白血球和血小板。成功的植入和功能性免疫系統的恢復對於患者的康復至關重要。造血幹細胞移植用於治療多種疾病，包括白血病、淋巴瘤、骨髓瘤、再生障礙性貧血和某些遺傳性疾病。根據加拿大癌症協會的數據，預計大約五分之二的加拿大人在其一生中會患上癌症，大約四分之一的人預計會死於這種疾病。僅在 2021 年，加拿大預計就有 229,200 人被診斷出癌症，而預計有 84,600 人死於該疾病。癌症仍然是加拿大人死亡的主要原因。

市場概況
預測期 2026-2030
2024 年市場規模 28.9億美元
2030 年市場規模 43.3億美元
2025-2030年複合年成長率 6.93%
成長最快的細分市場 骨髓移植
最大的市場 北美洲

該手術透過用健康細胞取代患病或功能失常的細胞，為面臨危及生命的血液相關疾病的患者提供了潛在的治癒或長期疾病控制。然而，HSCT也存在風險和併發症，其成功取決於捐贈者相容性和患者病情的特定特徵等因素。全球造血幹細胞移植（HSCT）代表了全球範圍內的一項重要醫療干預措施，為治療各種血液學和免疫學疾病提供了一種變革性方法。該手術在各大洲進行，影響著患有白血病、淋巴瘤、骨髓瘤和某些遺傳性疾病等疾病的不同族群。造血幹細胞移植的全球格局涉及醫療保健系統、研究機構和移植中心的共同努力，以促進先進療法的獲得。國際合作對於分享專業知識、最佳化移植方案和提高病患治療效果至關重要。捐贈者登記處和臍帶血庫在全球範圍內運作，為家庭圈子中缺乏合適匹配的患者提供潛在的捐贈者庫。全球造血幹細胞移植領域面臨的挑戰包括解決醫療保健基礎設施、捐助者可用性和影響患者獲取的社會經濟因素方面的差異。

主要市場促進因素

血液疾病的發生率增加

移植技術的進步

擴充應用

主要市場挑戰

捐贈者數量有限

移植相關的發病率和死亡率

主要市場趨勢

基因編輯和基因治療的進展

增加單倍體移植的使用率

細分市場洞察

應用洞察

類型洞察

區域洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：客戶之聲

第 5 章：全球造血幹細胞移植市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型（同種異體、自體）
    • 按適應症（白血病、淋巴疾病、骨髓瘤、其他）
    • 依應用分類（骨髓移植；周邊血幹細胞移植；臍帶血移植）
    • 按最終用戶（醫院藥房、零售藥房、專科診所）
    • 按地區（北美、歐洲、亞太地區、南美、中東和非洲）
    • 按公司分類 (2024)
  • 市場地圖
    • 按類型
    • 按指示
    • 按申請
    • 按最終用戶
    • 按地區

第 6 章：北美造血幹細胞移植市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按指示
    • 按申請
    • 按最終用戶
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 7 章：歐洲造血幹細胞移植市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按指示
    • 按申請
    • 按最終用戶
    • 按國家/地區
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第 8 章：亞太地區造血幹細胞移植市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按指示
    • 按申請
    • 按最終用戶
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲

第 9 章：南美洲造血幹細胞移植市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按指示
    • 按申請
    • 按最終用戶
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章：中東和非洲造血幹細胞移植市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按指示
    • 按申請
    • 按最終用戶
    • 按國家/地區
  • MEA：國家分析
    • 阿拉伯聯合大公國
    • 沙烏地阿拉伯
    • 南非

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 併購
  • 產品開發
  • 最新動態

第13章：波特的分析

第 14 章：PESTEL 分析

第15章：競爭格局

  • Pluristem Therapeutics Inc.
  • Lonza Group AG.
  • Regen Biopharma Inc.
  • Bluebird Bio Inc.
  • CellGenix GmbH
  • Novartis AG
  • Taiga Biotechnologies Inc.
  • Takeda Pharmaceutical Company Limited
  • Talaris Therapeutics Inc.
  • Merck & Co., Inc.

第 16 章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 20905

Global Hematopoietic Stem Cell Transplantation Market was valued at USD 2.89 billion in 2024 and is anticipated to reach USD 4.33 billion by 2030 with a CAGR of 6.93% during the forecast period. Hematopoietic Stem Cell Transplantation (HSCT), also known as bone marrow transplant, is a medical procedure used to treat various hematological and immunological disorders. The primary goal of HSCT is to replace or repair damaged or malfunctioning bone marrow and immune cells with healthy ones. Hematopoietic stem cells, which have the potential to develop into different types of blood cells, are crucial for this procedure. The process involves harvesting hematopoietic stem cells from the patient's bone marrow, peripheral blood, or umbilical cord blood. Alternatively, stem cells from a compatible donor can be used. Prior to transplantation, the patient undergoes a conditioning regimen, which typically involves chemotherapy and/or radiation therapy. This helps eliminate existing diseased cells and create a favorable environment for the new stem cells. After the conditioning phase, the harvested or donated stem cells are infused into the patient's bloodstream. These cells migrate to the bone marrow, where they begin to produce healthy blood cells, including red blood cells, white blood cells, and platelets. Successful engraftment and the restoration of a functional immune system are critical for the patient's recovery. HSCT is utilized to treat various conditions, including leukemia, lymphoma, myeloma, aplastic anemia, and certain genetic disorders. According to the Canadian Cancer Society, approximately 2 in 5 Canadians are projected to develop cancer during their lifetime, with about 1 in 4 expected to succumb to the disease. In 2021 alone, an estimated 229,200 individuals in Canada are anticipated to receive a cancer diagnosis, while 84,600 are expected to die from the condition. Cancer remains the leading cause of death among Canadians by a significant margin.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 2.89 Billion
Market Size 2030USD 4.33 Billion
CAGR 2025-20306.93%
Fastest Growing SegmentBone Marrow Transplant
Largest MarketNorth America

The procedure offers a potential cure or long-term disease control for patients facing life-threatening blood-related diseases by replacing the diseased or malfunctioning cells with healthy ones. However, HSCT also comes with risks and complications, and its success depends on factors such as donor compatibility and the specific characteristics of the patient's condition. Global Hematopoietic Stem Cell Transplantation (HSCT) represents a critical medical intervention on a worldwide scale, offering a transformative approach to treating various hematological and immunological disorders. This procedure is conducted across continents, impacting diverse populations facing conditions like leukemia, lymphoma, myeloma, and certain genetic disorders. The global landscape of HSCT involves a concerted effort by healthcare systems, research institutions, and transplant centers to facilitate access to advanced therapies. International collaboration is crucial for sharing expertise, optimizing transplant protocols, and enhancing patient outcomes. Donor registries and cord blood banks operate globally, providing a pool of potential donors for patients lacking a suitable match within their familial circles. Challenges in the global HSCT arena include addressing disparities in healthcare infrastructure, donor availability, and socioeconomic factors affecting patient access.

Key Market Drivers

Increasing Incidence of Hematological Disorders

The increasing incidence of hematological disorders serves as a pivotal driver for the Global Hematopoietic Stem Cell Transplantation (HSCT) Market. Hematological malignancies, such as leukemia, lymphoma, and myeloma, have witnessed a steady rise in prevalence globally, necessitating advanced therapeutic interventions. The escalating burden of these disorders has propelled the demand for HSCT, a transformative treatment modality that offers a potential cure for various blood-related diseases. As per data from the Leukemia & Lymphoma Society, approximately 1,519,907 individuals in the United States are either living with or in remission from leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS), or myeloproliferative neoplasms (MPNs). According to data from the Leukemia & Lymphoma Society, an estimated 397,501 individuals in the United States are either living with or in remission from leukemia. In 2021, approximately 61,090 new cases of leukemia are projected to be diagnosed. As populations age and environmental factors contribute to the growing prevalence of hematological malignancies, the role of HSCT becomes increasingly crucial in addressing unmet medical needs. The expanding scope of HSCT applications beyond malignant conditions to include non-malignant hematological disorders, autoimmune diseases, and certain genetic disorders further amplifies its market demand. As reported by the Leukemia & Lymphoma Society, approximately 163,878 adolescents and young adults (aged 15-39 years) in the United States are either living with or in remission from leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS), or myeloproliferative neoplasms (MPNs).

In the context of the increasing incidence of hematological disorders, the HSCT market is positioned as a cornerstone in the continuum of care. The procedure, involving the transplantation of hematopoietic stem cells to replace or repair damaged bone marrow, presents a viable therapeutic option for patients facing life-threatening conditions. The imperative to provide effective treatment options for the growing number of individuals diagnosed with hematological disorders has catalyzed research and technological advancements in the field of stem cell transplantation. Pharmaceutical companies, research institutions, and healthcare providers are collaboratively driving innovations to enhance the efficacy, safety, and accessibility of HSCT, aligning with the global imperative to confront the rising challenges posed by hematological diseases. As the prevalence of these disorders continues to escalate, the HSCT market is poised to play a pivotal role in offering hope and improved outcomes for patients worldwide.

Advancements in Transplantation Technologies

Advancements in transplantation technologies constitute a fundamental driver for the Global Hematopoietic Stem Cell Transplantation (HSCT) Market. Ongoing research and innovations in stem cell biology, immunology, and transplantation techniques have ushered in a new era of progress, enhancing the safety, efficacy, and accessibility of HSCT procedures. Technological breakthroughs have allowed for improvements in the identification, isolation, and manipulation of hematopoietic stem cells, optimizing their therapeutic potential. Refined conditioning regimens, including targeted and reduced-intensity approaches, contribute to minimizing the toxicities associated with the preparative phase of HSCT. Innovations in graft-versus-host disease (GVHD) prophylaxis and treatment strategies, such as novel immunosuppressive agents, aim to enhance the long-term outcomes and quality of life for transplant recipients. The integration of cutting-edge technologies, such as gene editing and gene therapy, holds promise for further revolutionizing HSCT. These technologies enable the modification of donor cells to enhance their compatibility and functionality, addressing challenges associated with graft rejection and immune complications. Advancements in cryopreservation techniques and supportive care measures contribute to the expansion of donor pools and improvement in post-transplant recovery. The collaborative efforts of researchers, clinicians, and industry stakeholders worldwide have led to the standardization of transplantation protocols, fostering international cooperation and knowledge exchange. As advancements continue to shape the landscape of transplantation technologies, the HSCT market benefits from a continuous cycle of refinement and innovation. These technological strides not only broaden the applicability of HSCT across a spectrum of hematological and non-malignant disorders but also underscore the commitment to improving patient outcomes and advancing the frontiers of regenerative medicine on a global scale. The trajectory of the HSCT market remains closely intertwined with the relentless pursuit of scientific excellence and the translation of groundbreaking technologies into transformative therapies for patients in need.

Expanding Applications

The Global Hematopoietic Stem Cell Transplantation (HSCT) Market is experiencing significant growth propelled by the expanding applications of this transformative therapy. Originally developed primarily for hematological malignancies such as leukemia and lymphoma, HSCT is now finding increasing utility across a broader spectrum of medical conditions. Beyond malignant disorders, HSCT has demonstrated efficacy in treating non-malignant hematological disorders, autoimmune diseases, and certain genetic disorders. The ability of hematopoietic stem cells to differentiate into various blood cell types and contribute to tissue repair makes HSCT a versatile therapeutic option. Autoimmune conditions like multiple sclerosis and systemic sclerosis, as well as inherited metabolic disorders like Hurler syndrome and adrenoleukodystrophy, are among the conditions benefiting from the expanding applications of HSCT.

This diversification in applications is fostering a more inclusive and patient-centric approach to HSCT, aligning with the evolving landscape of personalized medicine. As research continues to uncover the regenerative potential of hematopoietic stem cells, the scope of HSCT is likely to broaden further, encompassing additional rare diseases and disorders. In September 2021, the founders of QUINT, a project driving the mainstream adoption of DeFi, metaverse, token, and blockchain technologies, donated the equivalent of USD 16 million to the Al Jalila Foundation, part of the Mohammed Bin Rashid Al Maktoum Global Initiatives. The foundation is committed to transforming lives through medical innovation. This groundbreaking donation, the first of its kind in the UAE and the largest globally, aims to support the Hamdan Bin Rashid Cancer Charity Hospital through a custom-designed locking and vesting mechanism, ensuring the funds are made available to the foundation over the three-year construction period of the hospital's bone marrow transplant center. Upon completion, the facility will be named the "QUINT Bone Marrow Transplant Centre." Additionally, the QUINT token development team and strategic partners have made significant contributions toward this donation.

The growing success and acceptance of HSCT in these diverse applications reflect a paradigm shift in the understanding of its therapeutic potential. Collaborations between research institutions, healthcare providers, and pharmaceutical companies are pivotal in advancing the clinical evidence supporting these expanded applications, ensuring that HSCT continues to address unmet medical needs and offer hope for patients confronting a wide range of debilitating conditions globally. The increasing versatility of HSCT positions it as a cornerstone in the evolving landscape of regenerative medicine.

Key Market Challenges

Limited Donor Availability

Limited donor availability stands out as a prominent challenge in the Global Hematopoietic Stem Cell Transplantation (HSCT) Market. The success of HSCT hinges on finding a compatible donor, typically a human leukocyte antigen (HLA)-matched individual. However, the diversity of HLA profiles within populations, coupled with the underrepresentation of certain ethnic groups in donor registries, leads to challenges in identifying suitable matches. Ethnic and racial disparities in donor availability are particularly pronounced, affecting individuals from diverse backgrounds who may face difficulties in securing a donor with the necessary genetic compatibility. Efforts to address this challenge include the expansion of donor registries, the encouragement of voluntary stem cell donation, and increased awareness campaigns to diversify donor pools. International collaboration to share donor information globally and the exploration of alternative stem cell sources, such as cord blood and haploidentical donors, are strategies aimed at mitigating the impact of limited donor availability. However, these efforts require sustained commitment from healthcare organizations, policymakers, and the public to enhance the inclusivity and diversity of donor registries, ensuring that patients in need of HSCT have a higher likelihood of finding a suitable match, irrespective of their ethnic or racial background. The challenge of limited donor availability underscores the importance of global cooperation and advocacy to bridge gaps in access and equity within the HSCT landscape.

Transplant-Related Morbidity and Mortality

Transplant-related morbidity and mortality pose substantial challenges to the Global Hematopoietic Stem Cell Transplantation (HSCT) Market. Despite significant advancements in transplantation technologies, the procedure is associated with inherent risks that can impact patient outcomes. Complications such as infections, graft-versus-host disease (GVHD), organ damage, and treatment-related toxicities contribute to the morbidity and mortality rates associated with HSCT. Efforts to minimize these risks involve optimizing conditioning regimens, developing targeted GVHD prophylaxis, and enhancing supportive care measures. However, achieving a delicate balance between reducing adverse effects and maintaining the graft-versus-leukemia effect remains a complex challenge. Patient-specific factors, including age, overall health, and the underlying disease, further influence the risk profile. The high-intensity nature of preparative regimens contributes to the challenges, necessitating ongoing research into less toxic yet effective conditioning protocols. Addressing transplant-related morbidity and mortality involves a multifaceted approach that integrates advancements in medical technologies, personalized medicine, and comprehensive patient care strategies. Collaborative initiatives between healthcare providers, researchers, and pharmaceutical companies are essential to refining protocols, improving risk stratification, and enhancing post-transplant monitoring, ultimately ensuring safer and more successful outcomes for patients undergoing HSCT worldwide. Despite these challenges, the evolving landscape of HSCT remains focused on overcoming hurdles to provide life-saving treatments for individuals with hematological disorders.

Key Market Trends

Advancements in Gene Editing and Gene Therapy

Advancements in gene editing and gene therapy are pivotal trends shaping the Global Hematopoietic Stem Cell Transplantation (HSCT) Market. Cutting-edge technologies, such as CRISPR-Cas9, are revolutionizing the field by allowing precise modifications to the genetic makeup of hematopoietic stem cells. This progress is particularly significant in the context of HSCT, where genetically engineered cells can address challenges like graft-versus-host disease (GVHD) and improve compatibility between donors and recipients. In December 2021, Abatacept, a medication used to treat autoimmune diseases, became the first FDA-approved therapy to prevent acute graft-versus-host disease (GVHD) following hematopoietic stem cell transplantation. It is marketed by Bristol Myers Squibb under the brand name Orencia.

Gene editing enables the removal of undesirable traits or mutations from donor cells, reducing the risk of complications post-transplantation. Gene therapy approaches aim to enhance the therapeutic potential of HSCT by introducing or modifying genes to correct underlying genetic disorders. This not only expands the scope of HSCT applications to a broader range of diseases but also holds promise for developing curative treatments for genetic conditions. The continuous refinement of gene editing techniques and the exploration of novel gene therapies underscore the commitment to advancing the precision and effectiveness of HSCT. As these advancements progress, they contribute to the evolving landscape of personalized medicine and position HSCT as a cutting-edge therapeutic option with the potential to address unmet medical needs on a global scale. The integration of gene editing and therapy into HSCT protocols represents a transformative trend with profound implications for the future of regenerative medicine and stem cell transplantation.

Increased Utilization of Haploidentical Transplants

The increased utilization of haploidentical transplants is a noteworthy trend influencing the Global Hematopoietic Stem Cell Transplantation (HSCT) Market. Haploidentical transplantation involves the use of stem cells from a partially matched family member, typically a parent or a child. This approach has gained prominence due to advancements in transplant protocols and reduced intensity conditioning regimens, making it a viable option for patients lacking fully matched donors. The expanded use of haploidentical transplants addresses the challenge of limited donor availability, offering more patients the opportunity to undergo HSCT. Research efforts have focused on refining the procedure to minimize complications, such as graft-versus-host disease (GVHD), which historically posed challenges with haploidentical transplants. The growing acceptance of this approach represents a significant shift in the field, providing a potentially life-saving alternative for individuals facing hematological disorders. As technologies continue to improve and clinical outcomes are refined, the increased utilization of haploidentical transplants reflects a commitment to enhancing accessibility and broadening the applicability of HSCT, ultimately contributing to improved patient outcomes on a global scale. This trend underscores the adaptability and evolution of transplantation strategies, aligning with the goal of offering effective and personalized treatments to a more diverse patient population.

Segmental Insights

Application Insights

In 2024, Among the various applications in the Global Hematopoietic Stem Cell Transplantation Market, Bone Marrow Transplant (BMT) was the dominant procedure. BMT has a long-standing history of use and is widely considered the standard method for hematopoietic stem cell transplantation. The procedure involves the infusion of hematopoietic stem cells from the bone marrow of a donor or the patient's own marrow to replace damaged or diseased cells, particularly for treating hematologic malignancies like leukemia and lymphoma.

The dominance of Bone Marrow Transplant can be attributed to its established clinical protocols, well-documented efficacy, and broad range of applications. BMT is often the preferred choice for patients with severe bone marrow diseases, as it can effectively restore normal blood cell production. Advancements in matching techniques and immunosuppressive therapies have enhanced the success rates of BMT, making it a preferred option in both autologous and allogeneic transplants. The availability of bone marrow donors and the comprehensive understanding of the procedure have contributed to its widespread use. Although Peripheral Blood Stem Cell Transplant and Cord Blood Transplant are gaining traction, they have not yet surpassed Bone Marrow Transplant in terms of volume and prevalence. The continued reliance on BMT, supported by its robust clinical track record, makes it the leading application in the Global Hematopoietic Stem Cell Transplantation Market.

Type Insights

In 2024, among the various types of hematopoietic stem cell transplantation, Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) was dominating the Global Hematopoietic Stem Cell Transplantation Market. Allogeneic HSCT involves the transplantation of hematopoietic stem cells from a donor whose tissue type is closely matched to that of the recipient, often used to treat hematologic malignancies like leukemia, lymphoma, and myelodysplastic syndromes.

The dominance of Allogeneic HSCT can be attributed to its broader range of applications, particularly for patients with high-risk or relapsed hematologic cancers. The ability to use stem cells from a genetically matched donor allows for the replacement of the patient's diseased or damaged marrow, offering a potential cure for otherwise fatal conditions. The allogeneic approach offers the benefit of the donor's immune system, which can help fight residual cancer cells through the graft-versus-leukemia (GVL) effect.

Advancements in donor matching, improvements in immunosuppressive therapies, and enhanced supportive care have contributed to the increasing success rates of Allogeneic HSCT, making it the preferred choice for a wide range of patients. While Autologous HSCT, which involves using the patient's own stem cells, remains important for certain conditions like multiple myeloma, Allogeneic HSCT has proven to be more effective for patients with high-risk diseases or those lacking suitable autologous stem cell sources. As a result, Allogeneic HSCT continues to dominate the market due to its clinical versatility, successful outcomes, and ongoing advancements in donor and graft management.

Regional Insights

North America was the dominant region in the Global Hematopoietic Stem Cell Transplantation (HSCT) Market, driven by advanced healthcare infrastructure, significant investments in research and development, and a high level of awareness and adoption of HSCT treatments. The United States, in particular, plays a central role in this dominance due to its well-established healthcare system, leading medical institutions, and the presence of prominent stem cell transplant centers that offer state-of-the-art care for patients with hematologic malignancies and other serious conditions requiring HSCT. The prevalence of diseases like leukemia, lymphoma, and myeloma in North America has contributed significantly to the increased demand for hematopoietic stem cell transplantation. The region benefits from robust healthcare policies, insurance coverage, and reimbursement mechanisms that make these life-saving treatments more accessible to patients.

Advancements in technology, such as improved stem cell processing, better donor matching techniques, and innovations in post-transplant care, further position North America as a leader in the field. The region also attracts a high volume of clinical trials, which continually improve treatment protocols and patient outcomes. The growing collaboration between biotech companies, research institutions, and healthcare providers in North America has accelerated the development of novel stem cell therapies, further expanding the market. Due to these factors, North America maintains its position as the dominant force in the global HSCT market, with ongoing growth prospects as medical advancements continue.

Key Market Players

  • Pluristem Therapeutics Inc
  • Lonza Group AG
  • Regen Biopharma Inc.
  • Bluebird Bio Inc.
  • CellGenix GmbH
  • Novartis AG.
  • Taiga Biotechnologies Inc.
  • Takeda Pharmaceutical Company Limited
  • Talaris Therapeutics Inc.
  • Merck & Co., Inc.

Report Scope:

In this report, the Global Hematopoietic Stem Cell Transplantation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hematopoietic Stem Cell Transplantation Market, By Type:

  • Allogeneic
  • Autologous

Hematopoietic Stem Cell Transplantation Market, By Indication:

  • Leukemia
  • Lymphatic Disorder
  • Myeloma
  • Other

Hematopoietic Stem Cell Transplantation Market, By Application:

  • Bone Marrow Transplant
  • Peripheral Blood Stem Cell Transplant
  • Cord Blood Transplant

Hematopoietic Stem Cell Transplantation Market, By End User:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Specialty Clinics

Hematopoietic Stem Cell Transplantation Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Hematopoietic Stem Cell Transplantation Market.

Available Customizations:

Global Hematopoietic Stem Cell Transplantation Market report with the given Market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional Market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Types
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Hematopoietic Stem Cell Transplantation Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Allogeneic, Autologous)
    • 5.2.2. By Indication (Leukemia, Lymphatic Disorder, Myeloma, Other)
    • 5.2.3. By Application (Bone Marrow Transplant; Peripheral Blood Stem Cell Transplant; Cord Blood Transplant)
    • 5.2.4. By End User (Hospital Pharmacy, Retail Pharmacy, Specialty Clinics)
    • 5.2.5. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
    • 5.2.6. By Company (2024)
  • 5.3. Market Map
    • 5.3.1. By Type
    • 5.3.2. By Indication
    • 5.3.3. By Application
    • 5.3.4. By End User
    • 5.3.5. By Region

6. North America Hematopoietic Stem Cell Transplantation Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Indication
    • 6.2.3. By Application
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Hematopoietic Stem Cell Transplantation Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Indication
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada Hematopoietic Stem Cell Transplantation Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Indication
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico Hematopoietic Stem Cell Transplantation Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Indication
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By End User

7. Europe Hematopoietic Stem Cell Transplantation Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Indication
    • 7.2.3. By Application
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Hematopoietic Stem Cell Transplantation Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Indication
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By End User
    • 7.3.2. France Hematopoietic Stem Cell Transplantation Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Indication
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By End User
    • 7.3.3. United Kingdom Hematopoietic Stem Cell Transplantation Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Indication
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By End User
    • 7.3.4. Italy Hematopoietic Stem Cell Transplantation Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Indication
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain Hematopoietic Stem Cell Transplantation Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Indication
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By End User

8. Asia-Pacific Hematopoietic Stem Cell Transplantation Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Indication
    • 8.2.3. By Application
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Hematopoietic Stem Cell Transplantation Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Indication
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By End User
    • 8.3.2. Japan Hematopoietic Stem Cell Transplantation Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Indication
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By End User
    • 8.3.3. India Hematopoietic Stem Cell Transplantation Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Indication
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea Hematopoietic Stem Cell Transplantation Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Indication
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia Hematopoietic Stem Cell Transplantation Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Indication
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By End User

9. South America Hematopoietic Stem Cell Transplantation Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Indication
    • 9.2.3. By Application
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Hematopoietic Stem Cell Transplantation Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Indication
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By End User
    • 9.3.2. Argentina Hematopoietic Stem Cell Transplantation Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Indication
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By End User
    • 9.3.3. Colombia Hematopoietic Stem Cell Transplantation Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Indication
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By End User

10. Middle East and Africa Hematopoietic Stem Cell Transplantation Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Indication
    • 10.2.3. By Application
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. UAE Hematopoietic Stem Cell Transplantation Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Indication
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By End User
    • 10.3.2. Saudi Arabia Hematopoietic Stem Cell Transplantation Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Indication
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By End User
    • 10.3.3. South Africa Hematopoietic Stem Cell Transplantation Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Indication
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition
  • 12.2. Product Development
  • 12.3. Recent Developments

13. Porter's analysis

14. PESTEL analysis

15. Competitive Landscape

  • 15.1. Pluristem Therapeutics Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
  • 15.2. Lonza Group AG.
    • 15.2.1. Business Overview
    • 15.2.2. Company Snapshot
    • 15.2.3. Products & Services
    • 15.2.4. Financials (As Reported)
    • 15.2.5. Recent Developments
  • 15.3. Regen Biopharma Inc.
    • 15.3.1. Business Overview
    • 15.3.2. Company Snapshot
    • 15.3.3. Products & Services
    • 15.3.4. Financials (As Reported)
    • 15.3.5. Recent Developments
  • 15.4. Bluebird Bio Inc.
    • 15.4.1. Business Overview
    • 15.4.2. Company Snapshot
    • 15.4.3. Products & Services
    • 15.4.4. Financials (As Reported)
    • 15.4.5. Recent Developments
  • 15.5. CellGenix GmbH
    • 15.5.1. Business Overview
    • 15.5.2. Company Snapshot
    • 15.5.3. Products & Services
    • 15.5.4. Financials (As Reported)
    • 15.5.5. Recent Developments
  • 15.6. Novartis AG
    • 15.6.1. Business Overview
    • 15.6.2. Company Snapshot
    • 15.6.3. Products & Services
    • 15.6.4. Financials (As Reported)
    • 15.6.5. Recent Developments
  • 15.7. Taiga Biotechnologies Inc.
    • 15.7.1. Business Overview
    • 15.7.2. Company Snapshot
    • 15.7.3. Products & Services
    • 15.7.4. Financials (As Reported)
    • 15.7.5. Recent Developments
  • 15.8. Takeda Pharmaceutical Company Limited
    • 15.8.1. Business Overview
    • 15.8.2. Company Snapshot
    • 15.8.3. Products & Services
    • 15.8.4. Financials (As Reported)
    • 15.8.5. Recent Developments
  • 15.9. Talaris Therapeutics Inc.
    • 15.9.1. Business Overview
    • 15.9.2. Company Snapshot
    • 15.9.3. Products & Services
    • 15.9.4. Financials (As Reported)
    • 15.9.5. Recent Developments
  • 15.10. Merck & Co., Inc.
    • 15.10.1. Business Overview
    • 15.10.2. Company Snapshot
    • 15.10.3. Products & Services
    • 15.10.4. Financials (As Reported)
    • 15.10.5. Recent Developments

16. Strategic Recommendations

17. About Us & Disclaimer